The inhibition of IL‐6 signalling by Bazedoxifene and the benefits it conferred in murine pressure overload pathology might provide evidence for the potential role of Bazedoxifene in anti‐inflammatory therapy in HHD and even other cardiovascular diseases. Here, IL6 is linked to cardiovascular disorder.